Items Tagged with 'Boston Scientific FDA'
BSX Reports Net Sales of $1.828 Billion
On July 26, 2012, Boston Scientific Corporation (NYSE: BSX) released financial results for the second quarter ended on June 30, 2012.
BSX Acquires Cameron Health for $150 Million
On June 8, 2012, Boston Scientific Corporation (NYSE: BSX) closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its product portfolio the world's first and only commercially available subcutaneous implantable cardioverter defibrillator, called the S-ICD® System.
BSX Receives FDA Approval
On June 4, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System.
BSX Recieves FDA Pacemaker Approval
On May 7, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO™ and ADVANTIO™ pacemakers and INVIVE™ cardiac resynchronization therapy pacemakers (CRT-P).
On February 22, 2012, Boston Scientific Corporation's (NYSE: BSX) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval for use in patients experiencing an acute myocardial infarction (AMI), or heart attack.
On December 8, 2011, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous Lead for its Precision Plus™ Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.
On November 30, 2011, Boston Scientific Corporation (NYSE: BSX) announced FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators to treat heart failure and sudden cardiac death.
George Putnam has suceessfully invested in distressed companies for nearly 30 years and The Turnaround Letter's market-beating returns demonstrate the profit potential. He knows all the pitfalls, too--which he shares in this free report!
Distressed Investing Blog
10 of 2015's 12 sale recommendations have seen profits. Four of those stocks--GLW, WEN, FCH and BLDR--enjoyed total returns of 100% or higher, and our readers locked in an average gain of 69% with this year's closed out stock picks.
Your Financial Security is Serious Business...
so why should you trust The Turnaround Letter?
Ranked as #1 Performing Newsletter for 15-Yr. Returns: Turnaround Letter's 12.7% vs. S&P's 2.7%
28+ Years of Turnaround Investing Experience & Reliable Stock Market Advice
Diverse Monthly Stock Picks Personally Selected by George Putnam
2015 Stock Profit
George Putnam's Turnaround Letter has seen considerable stock profit in 2015: 10 of this year's 12 sale recommendations have seen increases.
Four of those enjoyed total returns of 100% or higher--and 2015's closed out stock picks have realized an average gain of 69% thus far.
2015 Stock Picks
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.